New USITC report shows "no credible evidence" supporting a TRIPs waiver expansion
The United States International Trade Commission (USITC) today released its “COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities” report. The report aims to analyze various issues and information gaps concerning COVID-19 diagnostics and therapeutics.
BIO’s Chief Policy Officer, John Murphy, made the following statement:
“This report reiterates our stance that there is no credible evidence supporting the need for an expanded TRIPs waiver -- or other expansions that would hinder critical intellectual property protections within the biomedical field -- to increase global access to COVID-19 diagnostics and therapeutics.
“Innovation and intellectual property go hand-in-hand. We look forward to advocating for American ingenuity and the global innovation ecosystem that ushers in new generations of treatments. We will continue to work with this Administration to find solutions that encourage innovation within the life sciences fields and increase patient access to critical diagnostics, therapeutics, and vaccines.”
Read the full USITC report here.
